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Abstract
This study supports the evidence that after vaccine‐related reactions, it is still possible to 
carry out the immunization protocol.
Out of more than 1000 patients per year evaluated for potential vaccine‐related risks 
(patients with chronic/serious diseases and events connected with vaccination), 76 (6%) 
presented previous vaccine adverse events (VAEs). The decision about whether to con‐
tinue child vaccination is made evaluating different factors: absence of specific contrain‐
dications, parents’ counseling, adequate hospital setting, choice of an appropriate and 
individualized schedule. None of the 76 children vaccinated after VAEs presented further 
side effects.
Our data demonstrate that VAE is not a recurring event. The real risk of a new VAE is 
mostly associated with the serious allergic reactions (IgE‐mediated anaphylaxis) and par‐
ents should be aware of this information, so that the widespread fear of VAE recurrence 
can be contained. Indeed, this type of concerns represents one of the main reasons for 
vaccination hesitancy, which leads to incomplete vaccination schedules.
Conclusions: This chapter encourages clinicians to take advantage of the available VAE 
assessment algorithms to objectively evaluate real vaccine risk of VAE and provide par‐
ents with correct information, considering that VAEs are rare and severe reactions are 
extremely rare.
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1. Introduction
A vaccine adverse event (VAE), also referred to as an adverse event following immunization, 
has been defined as “a medical incident that takes place after immunization, causes concern 
and is believed to be caused by the immunization” [1, 2]. These events are individual reac‐
tions usually induced by a direct effect of the vaccine or one of its components and are related 
with underlying medical conditions or idiosyncratic responses of the recipient. The adverse 
event may be any unfavorable or unintended sign, abnormal laboratory finding, symptom, 
or disease [3]. However, any untoward medical occurrence, which follows immunization and 
which does not necessarily have a causal relationship with the administration of the vaccine, 
is considered as VAE. These include also those conditions that would have occurred later on 
in life but are triggered earlier by the vaccination, like febrile seizures.
The adverse event may be a true adverse reaction that is induced by the vaccine, or may be 
caused by the way it is administered. Some events result from inappropriate practices, such 
as wrong dose, route, site or technique of administration, inappropriate intervals, incorrect 
preparation or amount of diluent, contamination, wrong storage, or ignored contraindications.
Other VAEs may be coincidental and would have occurred regardless of vaccination. These 
are purely temporally associated, because vaccines in children are given at an age when they 
are susceptible to many diseases. When a VAE is coincidental, the event would have occurred 
even if the individual had not been immunized. Sudden infant death syndrome (SIDS), for 
example, is an event clearly unrelated to vaccination; however, serious clinical events may be 
blamed to the vaccine by parents or community because of its close temporal association with 
immunization, especially if the vaccinated individual was previously healthy.
A vaccine safety surveillance program named Vaccine Adverse Event Reporting System 
(VAERS), run by the Center of Diseases Control and Prevention and Food and Drug Adminis‐
tration, has been instituted in 1990 in the US to collect information about VAEs [4]. In 1999, the 
World Health Organization (WHO) established the Global Advisory Committee of Vaccine Safety 
to respond promptly, efficiently, and with scientific rigor to vaccine safety issues of potential 
global importance. The last committee report edited on December 2015 is published and avail‐
able online [5].
The main concern for both clinicians and people is to be able to distinguish between a 
real VAE and another health problem that is just temporally coincidental and not related 
to vaccination. This is particularly true in our era of vaccine skepticism: due to parents’ 
frequent hesitation or outright refusal to accept some or all of the recommended vaccines, 
vaccination coverage is progressively decreasing [6]. The main reasons why people refuse 
vaccinations include ignorance about how vaccines work, which leads to an inappropriate 
criticism due to misunderstandings [7], and the negative influence by the media about vac‐
cination safety and efficacy [8]. Whatever the cause, VAEs can upset people to the point of 
refusing further vaccination for their children [9].
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To correctly interpret VAEs, the following characteristics need to be evaluated: the time cor‐
relation between vaccination and symptoms, the general health conditions of the subjects, and 
in particular their predisposition to allergies, and the known correlations between specific 
vaccines and clinical manifestations. In 2013, WHO edited the “User Manual for the revised 
classification on Causality assessment of adverse events following immunizations,” a guide 
to a systematic and standardized causality assessment process for VAEs [10]. The manual 
suggests to adopt a systematic approach considering both the population (i.e., statistical 
strength of association between vaccine and VAE, biological plausibility, and coherence of the 
association) and the individual (i.e., relationship between vaccine and VAE, clinical and/or 
laboratory proof of the association, and exclusion of alternative explanations) levels. Recently, 
some authors have proposed other “causality assessment schemes” to help clinicians distin‐
guish between VAEs whose association with the vaccination is consistent, indeterminate, or 
inconsistent [11].
1.1. Kinds of VAEs
The most typical and worrisome VAEs are allergic reactions, since reactions to the next dose 
of the same vaccine may be more immediate and severe than the first one, sometimes also 
life threatening [12]. Immediate allergic reactions are the most severe. These are relatively 
easy to identify because they are IgE‐mediated and can be detected either by skin prick tests 
(SPTs) or in vitro by specific IgE assay [13]. One of the most serious VAEs is anaphylaxis, 
which could have life‐threatening features: circulatory failure (altered level of conscious‐
ness, low blood pressure, weakness or absence of peripheral pulses, cold extremities due 
by reduced peripheral circulation, flushed face, and increased perspiration), with or with‐
out respiratory difficulties (bronchospasm and/or laryngospasm/laryngeal edema), nor‐
mally with rapid onset (minutes), an unpredictable clinical course, and variable severity. 
Over 80–90% of anaphylaxis also presented skin and mucous membrane manifestations. 
Diagnosis of anaphylaxis is supported by the presence, following administration of a vac‐
cine to a healthy recipient, of two or more of the above system signs and symptoms, which 
occur with a rapid onset. Anaphylactic reactions to vaccines are extremely rare but have the 
potential to be fatal.
It should be highlighted that the incidence of severe allergic reactions is very low, ranging 
between 0.5 and one cases/100,000 doses [14]. Currently, in Australia and US, anaphylaxis and 
encephalopathy are the only conditions determining absolute contraindication to revaccina‐
tion with the suspect vaccine [15, 16]. Allergic children can also be at risk of reactions against 
non‐active vaccine components, such as eggs/gelatin/antibiotics. Schemes with recommenda‐
tions for vaccination of such allergic children have been developed [17].
A kind of VAEs that are particularly worrisome for parents is hypotonia‐hyporesponsiveness 
episode (HHE), which is characterized by the sudden onset of pallor or cyanosis, decreased 
level or loss of responsiveness, and decreased level of muscle tone, occurring within 48 h 
of vaccination, normally transient and self‐limiting. These episodes have been described to 
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occur after vaccination with hexavalent vaccine and are considered to be related to the per‐
tussis component [18]. A review of Canadian tertiary‐care hospitals has shown that HHE 
accounts for less than five cases per 100,000 admissions to hospitalization, the majority of 
whom are discharged within 24 h [19]. Current evidences do not suggest that HHEs are asso‐
ciated with long‐term morbidity or mortality.
Febrile seizures are among VAEs of particular parents’ concern. However, febrile seizures 
are relatively common in children between 6 months and 5 years, and are more frequent in 
subjects with familiar and/or individual predisposition.
Other systemic reactions are fever, malaise, myalgia, irritability, headache, and loss of appetite. 
Inconsolable continuous crying lasting at least 3 h accompanied by high‐pitched screaming 
can occur. The arthralgia usually including the small peripheral joints is infrequent but can be 
persistent lasting longer than 10 days. Rarely rubella vaccine can cause an acute arthropathy 
that lasts 10 days. Guillain‐Barrè syndrome (GBS): acute onset of rapidly progressive, ascend‐
ing, symmetrical flaccid paralysis, without fever and with sensory loss could occur after 30–60 
days after immunization. Encephalopathy/encephalitis occurs within 72 h to 4 weeks after vac‐
cination, as an acute onset of seizures or severe alternation in the level of consciousness and/
or distinct change in behavior lasting 1 day or more. Idiopathic thrombocytopenic purpura 
(ITP) often follows measles vaccines. The timing and severity of these systemic reactions varies 
according to the characteristics of the vaccine received, the age of the recipient, and the indi‐
vidual biological response to each vaccine: it can start within a few hours to several days after 
vaccine.
A different kind of VAEs is represented by local reactions. These are frequently reported as 
“hypersensitivity reactions”: pain, swelling, or redness at the site of injection usually starting 
within a few hours are generally mild and self‐limiting. These are not allergic reactions, but 
may be due to a direct effect of the vaccine product, or be related to a higher antibody titers. 
Also, errors in vaccine preparation, in handling, or administration can cause local adverse 
effects, as purulence, inflammation, and positive Gram stain culture. Nodules at the injection 
site are relatively frequent and are constituted by a small well‐defined mass or a lump at the 
injection site, which are indicated as a subcutaneous nodule, antigen cysts, or granulomas, 
in the absence of abscess formation, erythema, and warmth. Local reactions are generally 
of moderate entity but can be significant at times, making parents and patients antonyms to 
revaccination. Local reactions are commonly observed following tetanus, pertussis, and diph‐
theria vaccine: reports demonstrated that the rate and severity increase with booster com‐
pared with primary doses of these antigens [20–25].
Another event that often occurs after vaccination is fainting. It is considered a vasovagal 
response and usually takes place in older children and adolescents who are prone to this kind 
of reaction. It is not considered to be a serious reaction and never represents a contraindica‐
tion to continue vaccination schedule. Canadians have proposed immunization guidelines on 
pain mitigation to help clinicians to prevent the aforementioned situations [26].
In our vaccine unit at the Bambino Gesù Pediatric Hospital in Rome, we visit about 1000 
patients per year and we evaluate those who have one or more risk factors for vaccination. 
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About 6% of patients at risk for vaccination has a history of VAE. The decision on the oppor‐
tunity to continue the vaccination schedule is made upon the evaluation of various factors. 
In case specific contraindications are not highlighted, we administer vaccines following a 
patient‐individualized schedule.
Here, we present the results of the analysis of data on patients with history of VAEs that came 
to our attention between September 2014 and February 2016.
2. Materials and methods
We included in our analysis all children who have been vaccinated at the Vaccine Unit of 
Bambino Gesù Children Hospital from September 10, 2014, until February 18, 2016. On a total 
of 1367 enrolled subjects, 76 children (6%) came to our unit with a previous history of one or 
more VAEs. In case of more than one VAEs, these were classified as “main event” and “sec‐
ondary event” depending on the severity of reported symptoms.
We recorded patients’ familial and personal history, predisposition to allergies, time correla‐
tion between vaccine administration and VAE, severity of referred VAE (i.e., grade 1: mild; 
grade 2: moderate; grade 3: severe), if the previous VAE has caused hospitalization, VAE 
duration, and sequela of the previous VAE.
Based on this general evaluation, we decided whether patients could continue to be vacci‐
nated or not. For those who were, we created a personalized vaccine schedule and provided 
them with a vaccination follow‐up plan in our unit.
3. Results
3.1. Previous, referred VAE
Patients’ characteristic: The median age of the 76 patients affected by a previous VAE was 3.9 
± 4 years.
VAEs type: The most common was urticaria/angioedema, which was referred by 31 out of 
76 patients (41%). Other common VAEs were hypotonia/sleepiness (11 patients = 14%), local 
symptoms (7 patients = 9%), high fever (6 patients = 8%), and low fever (5 patients = 7%). 
In our sample, seizures were relatively rare (3 patients = 4%). Anaphylaxis, the most severe 
VAE, was referred only by 1 patient after hexavalent vaccine administration. Guillain‐Barrè 
syndrome, another severe adverse event, was referred by 1 patient after mumps, measles, and 
rubella (MMR) vaccine (Table 1). Sixteen patients (21%) reported positive personal and/or 
familiar history regarding allergies. In all cases, the referred VAE was supposedly of allergic 
nature and the patient or his/her parents were allergic.
VAEs entity: The main referred VAE was classified as mild in 13 out of 76 patients (17%), mod‐
erate in 54 (71%), and severe in 9 (12%) patients. The mean time interval between vaccination 
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N reported events % on reported eventsa % on observed patientsb
Primary event
Local symptoms 7 9 0.5
Unusual crying 3 4 0.2
Urticaria/angioedema 31 41 2.3
Fever >40.5 6 8 0.4
Fever 38–40 5 7 0.4
Hypotonia/hyporesponsiveness 11 14 0.8
Seizures within 72 h 3 4 0.2
Guillain‐Barrè within 6 weeks 1 1 0.1
Purpura 3 4 0.2
Neurological symptoms other than 
seizures
3 4 0.2
Anaphylaxis 1 1 0.1
Gastrointestinal symptoms 1 1 0.1
hypothermia 1 1 0.1
Concomitant event
None 62 82 4.5
Local symptoms 2 3 0.1
Unusual crying 1 1 0.1
Urticaria/angioedema 1 1 0.1
Fever >40.5 2 3 0.1
Fever 38–40 4 5 0.3
Hypotonia/hyporesponsiveness 1 1 0.1
Seizures within 72 h 2 3 0.1
Gastrointestinal symptoms 1 1 0.1
VAEs characteristics
Severity grade 1 13 17
Severity grade 2 54 71
Severity grade 3 9 12
Time interval Mean, ±SD 26 h 72 h
Time interval Median, range 6 h 10 min to 480 h
VAE duration Mean, ±SD 82 h 189 h
VAE duration Median, range 48 h 30 min to 24 h
N. hospitalization 19 25
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and referred VAE was 26 ± 72 h. The mean duration of referred VAE was 82 ± 189 h. The longest 
referred VAEs were obviously Guillain‐Barrè syndrome, which lasted 60 days. Nineteen out of 
76 patients (25%) had been hospitalized after the previous VAE. No patient reported perma‐
nent sequela after the referred VAE (Table 1).
Correlation between specific vaccine(s) and kind of VAE: We found that the coadministration of 
hexavalent and PCV13 is the most commonly reported VAE (47 patients, 62.7%), followed 
by hexavalent alone (7 patients, 9%), MMR (5 patients, 6.7%), and DTaP (4 patients, 5%) 
(Table 2).
Type of reaction caused by specific vaccine(s): Coadministration of hexavalent and PCV 13 was 
most commonly associated with urticaria/angioedema (21 patients) and hypotonia/hypore‐
sponsiveness (8 patients). Administration of hexavalent alone was associated with various 
kinds of VAE (hypotonia/hyporesponsiveness, local symptoms, urticaria/angioedema, fever 
>40.5 grades, anaphylaxis, and fever 38–40 grades). MMR administration was associated 
with urticaria/angioedema, fever 38–40 grades, fever >40.5 grades, and Guillain‐Barrè syn‐
drome. DTaP administration was followed by local symptoms in 2 patients, and irritability 
or urticaria/angioedema in 1 patient each (Table 2).
N reported events % on reported eventsa % on observed patientsb
N. vaccinated that reported 
sequelae
0 ‐
N. positive familiar history for 
VAEs
16 21
aPercentage of events with respect to the number of patients with VAE (n. 76).
bPercentage of events with respect to the observed at‐risk patients (n. 1367).
Table 1. List of characteristics and types of VAEs.
Type of reaction Hexavalen DTaP/
IPV
Hex+PCV PCV13 MenB MMR Var MeC 
cayw
Flu HPV tot
Local symptoms 1 2 4 1 1 ‐ ‐ ‐ ‐ ‐ 9
Unusual crying ‐ ‐ 4 ‐ ‐ ‐ ‐ ‐ ‐ ‐ 4
Urticaria/
angioedema
1 1 21 ‐ 2 3 1 3 ‐ ‐ 32
Fever >4.5 1 ‐ 6 ‐ ‐ ‐ ‐ ‐ 1 ‐ 8
Fever 3 ‐ 5 ‐ ‐ 1 ‐ ‐ ‐ ‐ 9
Hypotonia/
hyporesponsiveness
1 ‐ 9 ‐ ‐ 1 ‐ ‐ ‐ 1 12
Seizures within 72 h ‐ ‐ 4 ‐ ‐ ‐ ‐ ‐ 1 ‐ 5
Guillain‐Barré 
within 6 weeks
‐ ‐ ‐ ‐ ‐ 1 ‐ ‐ ‐ ‐ 1
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3.2. Revaccination in Bambino Gesù Children Hospital
All patients that came to our unit with a history of VAE were evaluated for eligibility to con‐
tinue the vaccination schedule or to be revaccinated with further dose of the same vaccine. 
Out of the total number of 76 patients, 31 (41%) patients described a VAE of suspected allergic 
origin (i.e., urticaria/angioedema, anaphylaxis). Our approach to revaccination in patients that 
referred VAEs of suspected allergic nature is summarized in Table 3. All of these 31 patients 
underwent a skin prick test before revaccination with the same or a different vaccine: all skin 
tests resulted negative. All patients within our sample were further vaccinated one or more 
times. None experienced adverse events again.
Type of reaction Hexavalen DTaP/
IPV
Hex+PCV PCV13 MenB MMR Var MeC 
cayw
Flu HPV tot
Purpura ‐ ‐ 1 1 ‐ ‐ ‐ 1 ‐ ‐ 3
Irritability ‐ 1 2 ‐ ‐ ‐ ‐ ‐ ‐ ‐ 3
Anaphylaxis 1 ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ 1
Gastrointestinal 
symptoms
‐ ‐ 2 ‐ ‐ ‐ ‐ ‐ ‐ ‐ 2
Hypothermia ‐ ‐ 1 ‐ ‐ ‐ ‐ ‐ ‐ ‐ 1
Total events by 
vaccine type
8 4 59 2 3 6 1 4 2 1 90
Percentage of 
events by type
8.9 4.4 65.5 2.2 3.3 6.7 1.1 4.4 2.2 1.1 %
Table 2. Vaccine adverse events by the type of vaccine.


















32 (42%) Hexavalent + 
PCV13
21 4 6 5 6 None
DTaP 1 0 0 1 0 None
Hexavalent 1 0 0 1 0 None
MenB 2 2 0 0 0 None
MenC 2 0 0 0 2 None
MMR 3 0 0 3 0 None
Varicella 1 0 1 0 0 None
Men ACWY + B 1 0 0 0 0 None
Anaphylaxis 1 (1%) Hexavalent 1 0 0 1 0 None
Table 3. Immunization of allergic patients with a previous VAE.
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4. Discussion
In this report, we describe our experience with patients having a history of VAE who come to 
medical attention for vaccination counseling. In agreement with literature data, our findings 
show that VAEs are not common and that severe reactions are particularly rare [27]. Our data 
also demonstrate that VAEs are not recurring events, in general. This information should be 
shared with parents and patients, since they are often worried that VAE might reappear after 
subsequent vaccination events. Indeed, this is the most common reason leading to revaccina‐
tion refusal [9] and noncompletion of vaccination schedules [28].
The only specific risk of repeated VAEs regards those of allergic nature, in particular VAEs 
that can be interpreted as acute allergic reactions (i.e., IgE‐mediated). For this reason, it is 
important to perform accurate anamnesis and SPT in patients with referred VAEs of sus‐
pected allergic nature, using particular caution with patients who exhibit positive SPT (none 
in our sample). In 2010, Fritsche et al. have accurately described a diagnostic and therapeutic 
approach toward children with suspected vaccine allergy, highlighting the important role of 
STP and exposing the desensitization criteria to be employed for revaccination [29]. Based on 
our experience, when first reactions occur at a very young age and with more than one vac‐
cine, revaccinations are best approached “step by step,” with no more than one vaccine per 
visit, even in cases of negative SPT.
Our analysis indicates that the most “reactogenic” vaccine is hexavalent coadministered with 
PCV13. This could be explained both in terms of intrinsic immunogenicity of the vaccine itself 
and/or with the young age of the patients [13]. It has also been demonstrated that infants who 
receive hexavalent plus PCV7 have almost twofold higher incidence of reactions than those 
who received each vaccine alone [30, 31].
VAEs were described to be severe by 12% of parents and patients in our sample, a surprisingly 
high number. However, we deem as important to point out that we have frequently observed 
that a large gap exists between parents’/patients’ opinion and clinical evaluation about VAEs 
severity. People are often biased against and skeptical toward vaccines, and parents tend to 
interpret any child’s symptom that appears after immunization as worrisome. This phenom‐
enon acts as a statistical bias because probably we overestimated VAEs severity.
Two of our patients came with a history of very important VAEs. The first was a 12‐year‐old 
girl who referred a history of anaphylaxis after the third dose of hexavalent vaccine. The reac‐
tion occurred 1 h after vaccination and presented with urticaria, breathing and swallowing 
difficulty, and vomiting. The patient was brought to an emergency department where she was 
treated with epinephrine, fluids, and steroids. She was discharged after 3 days of hospitaliza‐
tion, in good health conditions. She and her parents denied any history of allergy. After this 
episode, her vaccine calendar was interrupted. In our vaccine unit, she was re‐vaccinated with 
MMR, after STP with the vaccine had resulted to be negative. Although she did not experi‐
ence any VAE, she will be re‐evaluated to decide whether she can undergo re‐vaccination 
with DTaP. The second patient who referred to our center with a history of serious VAE was 
a 7‐year‐old girl with a previous history of Guillain‐Barrè syndrome, which had occurred 
after the administration of the second dose of MMR. The syndrome appeared 3 weeks after 
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vaccination with leg weakness that led to walking impossibility within a few hours. She was 
admitted to the neurology department of our hospital, where she was promptly diagnosed 
and received immunoglobulin treatment. She was discharged after a period of 20 days in 
good general condition and did not experience any sequela nor relapse of the syndrome. After 
this episode, she did not receive any other vaccine. In our unit, she was re‐vaccinated follow‐
ing the routinary vaccination calendar and did not experience any further VAE.
Recent reports discuss the classification of VAEs and clarify the correct interpretation of the 
linkage between an adverse event and previous vaccination [11]; some authors propose algo‐
rithms to assess the linkage between VAE and vaccine [32]. According to those indications, a 
VAE is defined to be caused by the immunization if it is linked to a vaccine product‐related 
reaction, a vaccine quality defect‐related reaction, an immunization error‐related reaction, 
and an immunization anxiety‐related reaction. Other VAEs are defined as indeterminately 
related with the immunization, inconsistently related with the immunization and unclassifi‐
able. WHO published a causality assessment manual in which it is possible to follow a causal‐
ity assessment checklist to clarify the linkage between events and immunizations [10]. Indian 
guidelines classify VAEs in five broad categories: programmatic error, vaccine reaction, injec‐
tion reactions, coincidental, and unknown [33]. It is particularly important to distinguish 
between VAEs that are actually related to the vaccination (i.e., caused by the vaccination, 
indeterminately related to it, programmatic error, vaccine reaction, or injection reaction) and 
others, because the second are not reproducible and do not represent a contraindication to 
re‐vaccination. Clinicians should be familiar with these differences and encourage parents 
and patients to re‐vaccination when they refer VAE of the coincidental type. Following those 
schemes, patients in our sample reported VAEs that could be interpreted as being related to 
the vaccination, such as allergic and local reactions, as well as VAEs with indeterminate rela‐
tion with the vaccination, such as fever and unusual crying. It must be empathized that the 
first group comprises VAEs that are potentially reproducible and patients who should always 
be studied before re‐vaccination (by anamnesis, physical findings, and SPT). Conversely, the 
second group includes VAEs that are rarely reproduced and patients that can almost always 
be safely re‐vaccinated. As far as our two cases of severe VAE are concerned, anaphylaxis was 
related to vaccination and Guillain‐Barrè syndrome had an indeterminate relation with it. 
Both patients were re‐vaccinated, but we considered it to be important to make SPT before re‐
vaccination of the first patient and have not administered the causative vaccine of anaphylaxis 
yet. Notably, both patients had interrupted their vaccine calendar before coming to our atten‐
tion, but re‐vaccination resulted to be safe and neither of them experienced any complication.
5. Conclusion
In conclusion, we wish to empathize the concept that a history of VAE does not necessarily 
represent a contraindication to re‐vaccination, as well as encourage clinicians to take advan‐
tage of algorithms for VAEs assessment to evaluate the risk of reproducibility. It should be 
underlined that no classification provides certain proof in favor or against the existence of 
an association between an event and an immunization. Nevertheless, they provide valuable 
assistance to clinicians in the determination of the level of likelihood of specific associations. 
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To maintain public confidence in vaccines, it is important that advanced immunization pro‐
grams include pre‐ and postvaccination counseling for subjects at risk [34, 35].
In Italy, VAEs surveillance is mandatory and spontaneous reports of Adverse Events Following 
Immunization (AEFI) are collected by the National Network of Pharmaco‐vigilance, which 
includes the Italian Medicine Agency, the 20 regions and autonomous provinces of Trento and 
Bolzano, 204 local health units, 112 hospitals, 38 research institutes, and 561 pharmaceutical 
industries [36]. Every clinician and vaccine service should contribute to this surveillance and 
have access to all required data for accurate counseling to parents and patients, and to reas‐
sure them about the safety and importance of vaccines. In this era of widespread skepticism 
about vaccines, easily accessible as well as rigorous counseling is required more than ever.
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Glossary
VAE: any medical incident that takes place after immunization and is believed to be caused by 
the immunization itself. It is considered any unfavorable or unintended sign, and any abnor‐
mal laboratory finding, symptom, or disease
Causality assessment: linkage between a medical incident and a vaccine. Many authors have 
proposed causality assessment schemes that can be applied to help clinicians distinguish 
between events whose association with the vaccination is consistent, indeterminate, or 
inconsistent
Event caused by the immunization: an event that is attributable to a vaccine product‐related reac‐
tion, a vaccine quality defect‐related reaction, an immunization error‐related reaction, and an 
immunization anxiety‐related reaction
Coincidental adverse event: medical event that occurs after immunization but it is not caused 
by immunization itself, and would have occurred independently from the vaccination. In the 
case of coincidental adverse events, the relation between event and vaccine is only temporally
Temporal association: time interval between the vaccination and the adverse event. Temporal 
association is independent from causality and events that are temporally associated with vac‐
cines that may or may not be caused by the vaccines
Serious VAE: any VAE that causes a potential risk to the life/health of the recipient, that leads 
to hospitalization, and that causes disability/incapacity/congenital anomaly or birth defect.
Minor VAE: an event that is not serious and has no potential risk to the health of the recipient 
of the vaccine
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Reproducibility risk: risk that a VAE could reappear after another dose of the same/of another 
vaccine. The reproducibility risk is mostly significant for VAEs of allergic nature.
Vaccine pharmaco‐vigilance: the science of detection, assessment, understanding, and commu‐
nication of VAEs and other vaccine‐related issues
Immunization anxiety‐related reaction: an event that arises from anxiety about immunization
Immunization error‐related reaction: an event that is caused by an inappropriate vaccine han‐
dling, prescribing, or administration
Vaccine product‐related reaction: an event that is attributable to one or more properties of the 
vaccine product, whether the active component or one of the other components of the vaccine 
(adjuvants, preservatives, stabilizers)
Vaccine quality defect‐related reaction: an event that is attributable to one or more quality defects 
of the vaccine product, including defects of the administration devices
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